Drugs / Liposomal Bupivicaine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03496610 Comparator | Jan 2021 → Feb 2023 | — | Duke University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposomal Bupivicaine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03496610 ↗ |
| Route | Other | “Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound” NCT03496610 ↗ |